Announcements Trials
Browse Landscape

Phase

Phase 2 61Phase 1/2 58Phase 1 53Phase 3 30Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Recruiting 4Completed 4Unknown 3Not yet recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Leukemia, Myeloid, Acute 1Gastroenteropancreatic Neuroendocrine Tumors 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Injections × Clear all
NCT06788756 2026-04-29

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Moleculin Biotech, Inc.

Phase 2/3 Recruiting
312 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06282588 2026-03-19

THUNDER

Cancer Research Antwerp

Phase 2/3 Recruiting
493 enrolled
Genitourinary

Prostatic Neoplasms

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Bio-Thera Solutions

Phase 2/3 Recruiting
526 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡